Although Pfizer beat Merck to sell its next-generation pneumococcal vaccination, it lost a more important battle in June when the FDA said its competitor may provide its next-generation shot to new-borns and young children. Two months later, Pfizer, playing catch-up, has reacted with clinical evidence that might pave the way for the approval of its […]

The post Pfizer Provides Evidence To Back The Clearance Of Prevnar 20 first appeared on World Pharma Today.